Mexicos extended

UroToday.com – In defiance of two decades of experience, the clinical estimation of the prostate cancer tolerant in the context of PSA screening remains controversial. Many patients today drink a despicable jeopardy of disease-mutual mortality, and there is no run off consensus for their optimal treatment or whether they should be treated at all. Our study in the midst others has attempted to sub-classify these patients to identify those who have more aggressive cancer than suggested by the current standard of risk stratification.

Based on the findings, we advise that in summing-up to clinical organize, Gleason score, and PSA, prostate size and the amount of cancer present in the prostate biopsy should be considered for projection and counseling. Our hope is that the results will help clinicians provide off with recommendations in behalf of their patients; however, the optimal treatment strategy is hushed uncertain in many cases. As matter becomes available from endless clinical trials comparing surgery, radiotherapy, and delayed intervention, the urologic community settle upon benefit from further perspicacity into the management of patients with infirm risk prostate cancer.

Written by Eric Klein, MD as part of Beyond the Summary on UroToday.com. This hustle offers a method of publishing for the professional urology community. Authors are given an moment to extend on the circumstances, limitations, etc., of their research by referencing the published abstract.

Link to full digest

UroToday – the only urology website with original content written by global urology tenor opinion leaders actively plighted in clinical practice.

To access the latest urology story releases from UroToday, go to:
www.urotoday.com

—————————-
Copyright © 2007 – UroToday
Reproduced for Medical Statement Today with permission of UroToday.
—————————-

The most sturdy genetic critique of the DNA codes of onto 40,000 women — including those with breast cancer as well as those without the disease, has uncovered five stock genetic variants that growing an individual’s risk repayment for bust cancer.

In a paper published online in the journal Nature, the international team of scientists who conducted the genome-wide association study report that these five genes code for proteins crucial to biological activities that previously had not been implicated as triggers of breast cancer. The genes carry the DNA recipes for proteins important to the growth and duplication of body cells and the signalling, or communications, that must occur between cells in order for the body to function normally.

Previous investigations have identified about a dozen genetic mutations associated with breast cancer susceptibility. Normal versions of these genes help prevent cancer from occurring in the first place, by helping cells to repair DNA breaks and other abnormalities that can result from chance or exposure to an environmental toxin, such as excessive UV sunlight. However, BRCA-1, BRCA-2 and the other previously identified breast cancer susceptibility genes are mutated in a relatively small percentage of women.

“Risk mutations within these genes are so rare that only a very small number of breast cancer incidences are caused by these mutations,” said Jianjun Liu, Ph.D., co-author of the Nature paper and Senior Research Scientist at the Genome Institute of Singapore, one of the over 20 research institutions collaborating in the international study of breast cancer genes.

The five genetic variants identified by Dr. Liu and collaborators occur more frequently among women with breast cancer than do BRCA and the other previously identified breast cancer susceptibility genes.

The five genes are the FGFR2, TNRC9/ LOC643714, MAP3K1, and LSP1.

“This is a truly landmark breakthrough for breast cancer research, because these genes are the first confirmed common genetic risk factors for breast cancer,” said Dr. Liu.

As common genetic risk factors, these genes likely have more impact than the previously identified risk genes on disease prevalence across a large population of women. However, Dr. Liu pointed out, breast cancer susceptibility is conferred by a large number of genetic loci, each with a small effect on breast cancer risk.

“Breast cancer likely involves many risk genes, and each gene only confers a moderate risk for disease,” Dr. Liu explained.

While the findings of the international research collaboration hopefully will fuel the development of more effective ways of preventing and treating breast cancer, Dr. Liu said that the most immediate benefit of the new results may be in understanding the molecular mechanisms of breast cancer.

The Nature paper is the second major research report published this year by this international team of scientists. In February of this year, the team reported in Nature Genetics that they had identified a gene (Caspase that could reduce cancer risk by as much as 10 percent.

The international research collaboration, known as the Breast Cancer Association Consortium, was established in 2005 to provide large sample sizes for examining genetic associations. In addition to GIS, participants include the Karolinska Institute with which the GIS has several other collaborations, and scientific institutions in other countries of Europe, as well as the U.S., and Australia.

http://www.a-star.edu.sg/

Long-chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) have benefits in any event cardiovascular and inflammatory function, certain types of cancer, and caring and infant salubrity, according to recent become visible-reviewed studies.

These beneficial fatty acids are found naturally in fatty fish, but breakthrough research shows that bioengineered plants can produce them. Summaries of these studies are presented in the June 2004 issue of the PUFA Newsletter.

Plants make the precursors of LC-PUFAs, but are unable to synthesize the beneficial long-chain forms. Researchers at Bristol University, U.K., introduced three genes involved in converting PUFAs into LC-PUFAs into mouse ear cress (Arabidopsis thaliana). Significant amounts of n-3 LC-PUFAs were produced by the biotech cress.

“Using biotechnology to produce LC-PUFAs in oilseed crops would greatly expand the availability of these beneficial fatty acids in food and feed for human and animal nutrition,” says PUFA Newsletter editor Joyce A. Nettleton, D.Sc. “This is extremely promising research.” Another landmark study reported that the risk of blood and lymph cancers, including leukemia, non-Hodgkin’s lymphoma, and myeloma, is inversely related to fish consumption. This relationship is particularly strong for leukemia in men.

“The significant reduction in cancer risk is associated with the increased proportion of dietary energy from fish,” Nettleton says. “Blood and lymph cancers have received less attention than hormone-linked cancers.”

New cardiovascular studies suggest that heart arrhythmia can be mitigated with n-3 LC-PUFAs and heart risk factors in postmenopausal women reduced with the consumption of docosahexaenoic acid (DHA), an n-3 LC-PUFA. The former study provides direct evidence that omega-3s can inhibit abnormally rapid heartbeats. In the latter study, DHA supplementation in postmenopausal women, independent of hormone therapy status, decreased their serum triglycerides by 20% and increased their “good” cholesterol by 8%.

All of these research findings are good news in light of a prediction in the June 2004 PUFA Newsletter that by the year 2020, the top health burdens worldwide will be cardiovascular disease, perinatal conditions, and mental illnesses. These problems are linked to a distorted pattern of fatty acid consumption that can be mitigated by n-3 LC-PUFAs.

“It’s the type of fat, not the amount, that is key,” Nettleton concluded. The quarterly PUFA Newsletter is sponsored by DSM Nutritional Products, Inc., of The Netherlands.

http://www.fatsoflife.com .